These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21449013)

  • 21. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 22. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Parkinson's disease. From theory to practice.
    Ahlskog JE
    Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Initial management and adaptation of Parkinson's disease treatment].
    Gérard JM
    Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease.
    Clarke CE; Moore AP
    Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
    [No Abstract]   [Full Text] [Related]  

  • 28. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
    Prakash KM; Kek PC
    Parkinsonism Relat Disord; 2010 Dec; 16(10):691-2. PubMed ID: 20729126
    [No Abstract]   [Full Text] [Related]  

  • 32. The variability of levodopa response in Parkinson's disease: is sensitization reversible?
    Jabre MG; Bejjani BP
    Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452
    [No Abstract]   [Full Text] [Related]  

  • 33. [Parkinson's disease, familial Parkinson's disease].
    Kondo T
    Nihon Rinsho; 2004 Jan; 62 Suppl():97-101. PubMed ID: 15011328
    [No Abstract]   [Full Text] [Related]  

  • 34. Drugs for Parkinson's disease.
    Cranwell-Bruce LA
    Medsurg Nurs; 2010; 19(6):347-9, 355; quiz 350. PubMed ID: 21337993
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinson's goal: ease symptoms, slow progression.
    Johns Hopkins Med Lett Health After 50; 2006 Jun; 18(4):4-5. PubMed ID: 16795901
    [No Abstract]   [Full Text] [Related]  

  • 36. Parkinson's disease. Second of two parts.
    Lang AE; Lozano AM
    N Engl J Med; 1998 Oct; 339(16):1130-43. PubMed ID: 9770561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excitability of the lower-limb area of the motor cortex in Parkinson's disease.
    Vacherot F; Attarian S; Eusebio A; Azulay JP
    Neurophysiol Clin; 2010 Aug; 40(4):201-8. PubMed ID: 20674816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.